Drugs / levonogestrel
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05064332 | Oct → Dec 2021 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03608241 | Sep → Nov 2018 | — | Pfizer | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06145438 | Sep 2023 → Aug 2024 | ovarian endometriosis | Universitas Diponegoro | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT02669238 Comparator | May 2018 → Oct 2019 | endometriosis | Centre Hospitalier Universitaire de la Réunion | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Levonogestrel | “First line: Minidril® (Levonogestrel 0.15 mg / Ethinylestradiol 0.03 mg) Second line: Leeloo® (Levonogestrel 0.1 mg / Ethinylestradiol 0.02 mg)” NCT02669238 ↗ |
| Route | Oral | “Single dose of Oral tablet containing 30 ug EE and 150 ug of LN” NCT03608241 ↗ |